Synairgen plc (SYGGF)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Mar 5, 2026, 4:00 PM EST
-99.97%
Market Cap 110.27K
Revenue (ttm) n/a
Net Income (ttm) -8.53M
Shares Out 1.10B
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 3,524
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta 4.52
RSI 32.83
Earnings Date May 28, 2026

About Synairgen

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 34
Stock Exchange OTCMKTS
Ticker Symbol SYGGF
Full Company Profile

Financial Performance

Financial numbers in GBP Financial Statements

News

There is no news available yet.